Skip to main content

Table 2 Patient classification and time to treatment outcomes

From: Favorable outcomes with reduced steroid use in juvenile dermatomyositis

  Monocyclic, n = 10 Chronic Continuous, n = 18  
Myositis control (months) 6.6 (4.3–7.8)
(n = 10)
6 (3.7–17.6)
(n = 17)
p = 0.334
Cutaneous disease control (months) 15.7 (13.1–17)
(n = 9)
29.6, (16.4–63.3)
(n = 12)
p = 0.018
Duration of steroid use (months) 8 (4.5–8.8)
(n = 9)
9.9 (7–30.4)
(n = 18)
p = 0.145
  1. Median value with interquartile range is shown for time to myositis control, cutaneous disease control, and duration of steroid use for JDM patients with monocyclic and chronic continuous disease courses. Statistical significance is denoted by a p value less than 0.05